Parathyroid Disorders. Группа авторов

ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA: Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 2015;73:1–7.

8Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL: Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122–1129.

9Yu N, Donnan PT, Murphy MJ, Leese GP: Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009;71:485–493.

10Walker MD, Silverberg SJ: Primary hyperparathyroidism. Nat Rev Endocrinol 2018;14:115–125.

11Bilezikian JP, Bandeira L, Khan A, Cusano NE: Hyperparathyroidism. Lancet 2018;391:168–178.

12Marcocci C, Cetani F, Rubin MR, et al: Parathyroid carcinoma. J Bone Miner Res 2008;23:1869–1880.

13Li Y, Simonds WF: Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer 2015;23:R229–R247.

14Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh QY, Clark OH: Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg 1995;180:81–87.

15Sharretts JM, Simonds WF: Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 2010;24:491–502.

16Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP: Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3580–3594.

17Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP: Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98:2734–2741.

18Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3570–3579.

19Zanocco KA, Yeh MW: Primary hyperparathyroidism: effects on bone health. Endocrinol Metab Clin North Am 2017;46:87–104.

20Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D, Pepe J, Piemonte S, Scillitani A, Minisola S, Bilezikian JP: Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 2015;100:1309–1315.

21Castellano E, Attanasio R, Gianotti L, Cesario F, Tassone F, Borretta G: Forearm DXA increases the rate of patients with asymptomatic primary hyperparathyroidism meeting surgical criteria. J Clin Endocrinol Metab 2016;101:2728–2732.

22Vestergaard P: Primary hyperparathyroidism and nephrolithiasis. Ann Endocrinol 2015;76:116–119.

23Marchini GS, Faria KVM, Torricelli FCM, Monga M, Srougi M, Nahas WC, Mazzucchi E: Sporadic primary hyperparathyroidism and stone disease: a comprehensive metabolic evaluation before and after parathyroidectomy. BJU Int 2018;121:281–288.

24Walker MD, McMahon DJ, Inabnet WB, et al: Neuropsychological factors in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009;94:1951–1958.

25Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D’Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J: Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011;26:2317–2337.

26Cheng Z, Zou S, Peng D, Zhang G, Zhu X: Prognostic value of ^99mTc-sestamibi parathyroid scintigraphy in predicting future surgical eligibility in patients with asymptomatic primary hyperparathyroidism. Clin Nucl Med 2018;43:151–154.

27Sun B, Guo B, Wu B, Kang J, Deng X, Zhang Z, Fan Y: Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporos Int 2018;29:635–642.

28Stephen AE, Mannstadt M, Hodin RA: Indications for surgical management of hyperparathyroidism: a review. JAMA Surg 2017;152:878–882.

29Consensus Development Conference Panel: Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593–597.

30Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353–5361.

31Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009;94:335–339.

32Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

33Rubin MR, Bilezikian JP, McMahon DJ, et al: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462–3470.

34Polistena A, Lucchini R, Monacelli M, Triola R, Avenia S, Barillaro I, Johnson LB, Sanguinetti A, Avenia N: Current indications for surgical treatment of primary hyperparathyroidism in the elderly. Am Surg 2017;83:296–302.

35Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux